PCI Biotech Holding ASA (OSL:PCIB)

Market Cap	5.97M -87.4%
Revenue (ttm)	4.69M -21.9%
Net Income	-20.54M
EPS	-0.55
Shares Out	37.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	369,236
Average Volume	2,509,458
Open	0.1700
Previous Close	0.1665
Day's Range	0.1600 - 0.1700
52-Week Range	0.0900 - 2.2200
Beta	0.79
RSI	43.31
Earnings Date	May 8, 2026

About PCI Biotech Holding ASA

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities. It ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 5
• Stock Exchange: Oslo Børs
• Ticker Symbol: PCIB

Financial Performance

In 2024, PCI Biotech Holding ASA's revenue was 6.74 million, an increase of 125.25% compared to the previous year's 2.99 million. Losses were -16.42 million, -19.19% less than in 2023.